Back to results
US 12,589,165 B2Granted
Methods for treating bladder tumors with viral nanoparticle conjugates and immune checkpoint inhibitors
AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Services, Aura Biosciences, Inc.
InventorsElisabet de los Pinos, John Todd Schiller, Rhonda C. Kines
Life of this patent
Estimating the term…
Abstract
Some embodiments of the present disclosure are directed to methods and compositions for the treatment of tumors, using a combination of immunotherapeutic agents and tumor-targeting viral capsid protein assemblages comprising anti-cancer molecules conjugated to viral capsid proteins.
Claims20
A method for treating a bladder tumor, comprising:
- (a) administering to a primary bladder tumor in a subject a composition comprising a virus-like particle conjugate that comprises (i) human papillomavirus capsid proteins and photosensitive molecules, wherein the photosensitive molecules are conjugated to the human papillomavirus capsid proteins, wherein the composition is administered via intralesional injection;
- (b) administering to the primary bladder tumor in the subject a composition comprising an immune checkpoint inhibitor selected from anti-PD-1 antibodies, anti-CTLA-4 antibodies, and anti-LAG3 antibodies, wherein the immune checkpoint inhibitor is administered via intravenous or intravesical injection;
- and
- (c) activating the photosensitive molecules using an infrared laser, a near-infrared laser, or an ultraviolet laser.
1 more element
A method for treating a bladder tumor, comprising:
- (a) administering to a primary bladder tumor in a subject a composition comprising a virus-like particle conjugate that comprises (i) human papillomavirus capsid proteins and photosensitive infrared dye molecules, wherein the photosensitive molecules are conjugated to the human papillomavirus capsid proteins, wherein the composition is administered via intralesional injection;
- (b) administering to the primary bladder tumor in the subject a composition comprising an immune checkpoint inhibitor selected from pembrolizumab, nivolumab, and ipilimumab, wherein the immune checkpoint inhibitor is administered via intravenous or intravesical injection;
- and
- (c) activating the photosensitive infrared dye molecules using an infrared laser.
1 more element
Dependencies are inferred from the claim text.